Impact Statement MHRA – New Rules from January 2021
09 October 2020
Posted by: Tamsin Marshall
The UK has left the EU, and the transition period after Brexit comes to an end this year.
From 1 January 2021, the Medicines and Healthcare products Regulatory Agency (MHRA) will be the UK’s standalone medicines and medical devices regulator.
Transition from the EU allows the UK to offer fully independent regulatory decisions for both devices and pharmaceuticals, both nationally and in joint work with other international regulators.
Stakeholders need to get ready for new rules from 1 January 2021.
The MHRA has published details of what you what you'll need to do from 1 January 2021. The information will be updated if anything changes.
Click on the following link to see the detailed MHRA notifications:-New Rules for 2021
You can also check what else you need to do during the transition period.
Readers may also be interested to see comment on the changes from The Association of British Pharmaceutical Industries (ABPI) ABPI response statement
Download this document
Prepared by Malcolm Holmes C.Chem MRSC
Please feel free to share this article via the share button above.